Chugai Group | Contact Us | Sitemap

INNOVATION BEYOND IMAGINATION

With unprecedented ideas, the company continuously creates value beyond our conventional ideas and expectation.

Technology

CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.

Sustainability

ESG at Chugai Group

Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.

The next big drug discovery is in your hands.

The next big drug discovery is in your hands.

News Release

Browse through the latest news and developments by CPR and the Chugai Group.

Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Source: Chugai Pharmaceutical: News Releases June 30, 2020
Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
Source: Chugai Pharmaceutical: News Releases June 29, 2020
Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint
Source: Chugai Pharmaceutical: News Releases June 19, 2020

Careers at Chugai

If you possess the passion to make the next big drug discovery, you’ll find that a career with CPR will help take you further!